By: Adam Feuerstein | 01/29/14 - 09:32 AM EST(MDVN) shares are up 14% to $86.36 in early Wednesday trading following the release last night of very strong Xtandi data from the "PREVAIL" phase III study in pre-chemo prostate cancer patients.
In our view, the full phase 3 PREVAIL data of Xtandi in pre-chemo prostate cancer (PC) leave little room for debate on whether Xtandi or JNJ's Zytiga will have majority market share. We acknowledge the caveats of cross-trial comparisons, but in our judgment, many of the efficacy metrics definitively favor Xtandi. Importantly, Xtandi also wins on convenience metrics which are commercially relevant (no need for steroids, 1x/day, no food effect). Overall, we believe that the profile of Xtandi in pre-chemo PC should be very attractive to both urologists and oncologists, with the former being largely untapped and critical for upstream use. We suspect that utilization may accelerate in the US prior to YE14e label expansion and as such, we are raising our 2014-2016 WW forecasts by 5-20% given increasing duration of therapy and higher market share for Xtandi. Yesterday, we raised our Dec 2014 target to $85 from $75 based on what we thought would be a differentiated clinical profile of Xtandi. Today, we are raising our Dec 2014 target to $101 from $85 based on emergence of real phase 3 data which we believe positions Xtandi as the clear winner in pre-chemo, justified by higher forecasts and additional upside levers.
PREVAIL data is profoundly impressive. There is no ? that a 17 month delayed to chemo & 81% radiographic response is better than abi trial daviesbj (@daviesbj) January 28, 2014
Urologists and patients are absolutely going to LOVE that 17-month median delay to chemo slide. $MDVN Zytiga was only 8.4 months David Miller (@AlpineBV_Miller) January 28, 2014[Disclosure: Miller is long Medivation.]
All in, last night's Xtandi data are a big boost to the Medivation bull thesis.
Following the data release, we spoke to our urologist consultants. It was referred to as "great data" and a "home run" - when pressed to find a weak point in the data, they could not.Ultimately, the urologists - in contrast to the oncologists - appear focused on endpoints around disease abatement, e.g. response rates and progression-related endpoints. Indeed what one urologist said particularly resonated with him was (1) the 17 month delay on the time to chemotherapy (Exhibit 2), which was about twice the benefit seen with Zytiga and (2) the 78% PSA 50 response (Exhibit 3). Ultimately, our consultants said current utilization of Zytiga and Xtandi has largely been in-line with the current labels (Zytiga pre-chemo and Xtandi post-chemo), but expected utilization to change once Xtandi has a pre-chemo label and reimbursement, which we think could happen later this year in the US. Once that happens, they expected to use Xtandi first in all pre-chemo patients.
10/15/14 - 04:07 PM EDT
10/14/14 - 10:53 AM EDT
10/08/14 - 03:52 PM EDT
10/08/14 - 11:33 AM EDT
10/08/14 - 10:38 AM EDT
10/19/14 - 16:21 PM EDT
10/18/14 - 15:04 PM EDT
10/17/14 - 12:36 PM EDT
10/17/14 - 12:33 PM EDT
10/17/14 - 11:50 AM EDT
Access the tool that DOMINATES the Russell 2000 and the S&P 500.